Tests ONM-501 injected into tumors, alone or with cemiplimab, in advanced cancers
Tests ONM-501 injected into tumors in adults with advanced solid tumors or lymphomas.
Plain-language title generated from the registry record
Registry title: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Key facts
- Where
- Bedford Park, Buderim, Darlinghurst, Southport, Subiaco, Wollongong, and Woolloongabba, AustraliaSee the 7 sites
- Phase
- Phase 1
Where in Australia
- Southern Oncology Clinical Research UnitBedford Park, AustraliaNo longer taking part
- University of the Sunshine Coast Clinical TrialsBuderim, AustraliaTaking people
- St Vincent's HospitalDarlinghurst, AustraliaTaking people
- Tasman Oncology ResearchSouthport, AustraliaTaking people
- St. John of God Subiaco HospitalSubiaco, AustraliaNo longer taking part
- Cancer Care WollongongWollongong, AustraliaTaking people
- Princess Alexandra Hospital | Metro South HealthWoolloongabba, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- OncoNano Medicine, Inc.
- Trial code
- NCT06022029
- Record updated
- 24 December 2025
- Original description
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.Read full original descriptionShow less
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Inclusion: Ability to understand and willingness to sign written informed consent before performance of any study procedures; Age ≥ 18 years; Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists; Participants must have a minimum of one injectable and measurable lesion; Participants with prior Hepatitis B or C are eligible if they have adequate liver function; Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load <400 copies/mL, and have CD4+ T-cell (CD4+) counts ≥ 350 cells/uL; Adequate bone marrow function:; Adequate liver function.
Exclusion: Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy; Major surgery within 4 weeks before the first dose of study drug; Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion; Has uncontrolled or poorly controlled hypertension as defined by a sustained BP > 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter; Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501; Has a condition requiring systemic treatment with corticosteroids; Has an active infection requiring systemic treatment; Has known hypersensitivity to any component in the formulation of cemiplimab; Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (>10 mg daily prednisone equivalent); Prolongation of corrected QT (QTc) interval to >470 millisecond (ms) for males and females when electrolytes balance is normal; Females who are breastfeeding or pregnant at screening or baseline; Females of childbearing potential that refuse to use a highly effective method of contraception; Is participating in another therapeutic clinical trial; Additional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b).